Revvity price target lowered to $140 from $146 at Raymond James

Raymond James analyst Andrew Cooper lowered the firm’s price target on Revvity (RVTY) to $140 from $146 and keeps an Outperform rating on the shares. The firm is taking a modestly conservative tack on the recovery ramp for Life Sciences Tools & Services through 2025 as well as layering in a substantially more significant foreign exchange headwind given movement in the dollar since Q3 results, the analyst tells investors in a research note. Revvity is the firm’s favorite of the group, which remains underappreciated in terms of strength of the base that should allow for another year at or near the front of the pack on organic growth.